| Stereochemistry | ACHIRAL |
| Molecular Formula | C7H5IN2O3 |
| Molecular Weight | 292.0307 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)C1=CC(=C(I)C=C1)[N+]([O-])=O
InChI
InChIKey=MDOJTZQKHMAPBK-UHFFFAOYSA-N
InChI=1S/C7H5IN2O3/c8-5-2-1-4(7(9)11)3-6(5)10(12)13/h1-3H,(H2,9,11)
| Molecular Formula | C7H5IN2O3 |
| Molecular Weight | 292.0307 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Iniparib (BSI-201 or 4-iodo-3-nitrosobenzamide) inactivated poly(ADP-ribose) polymerase by zinc ejection from the first zinc finger of this nuclear protein. Iniparib, either alone or in combination with chemotherapy, had significant antitumor activity in preclinical studies in vitro and in vivo. In June 2013, Sanofi dropped the drug after it failed in a phase III trial of patients with squamous non–small-cell lung cancer and a phase II trial in platinum-resistant ovarian cancer.
CNS Activity
Originator
Approval Year
Cmax
AUC
T1/2
Doses
AEs
Sourcing
PubMed
Sample Use Guides
A Phase 2, single arm study of Iniparib in patients with BRCA1 or BRCA2 associated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. Patients received iniparib intravenously at a dose of 8mg/kg twice weekly.
Route of Administration:
Intravenous
